CardioExchange Archive

January 18th, 2013

Media Coverage of Research: Does It Sometimes Miss the Point?

Harlan M. Krumholz, MD, SM

Observing media coverage of a new study, Harlan Krumholz wonders if the spin misses the point of the research.

---

January 14th, 2013

You’re Sick: To Work, or Not to Work?

Harlan M. Krumholz, MD, SM

When you’re sick do you feel torn between meeting your obligations and protecting patients from your illness?

---

January 9th, 2013

Niacin Therapy in the Crossfire

William Edward Boden, MD and Harlan M. Krumholz, MD, SM

William E. Boden, lead investigator of the AIM-HIGH trial, and CardioExchange’s Harlan M. Krumholz debate the current state of research on niacin therapy.

---

October 5th, 2012

A Plea For Open Science And Data Sharing

Harlan M. Krumholz, MD, SM

I am still out pushing the cause of open science and data sharing. Something we can do better through the scientific community. It starts with the will – and a focus on societal good. The ‘how’ is challenging – but the problems can be solved. Earlier this week I gave a talk at an Institute of Medicine […]

---

September 26th, 2012

Treading Water During the Post-MI Waiting Period

Harlan M. Krumholz, MD, SM and James Fang, MD

Does your institution use the LifeVest strategy routinely during the waiting period after an MI?

---

September 19th, 2012

An Ad That Doesn’t Tell the Entire Story — Part 2: Niaspan

Harlan M. Krumholz, MD, SM

A print ad for Niaspan focuses only on how it raises HDL-cholesterol levels, with no mention of the lack of benefit in improving outcomes.

---

September 11th, 2012

Advertising That Falls Short — Part 1: Omega-3 Fatty-Acid Supplements

Harlan M. Krumholz, MD, SM

What is the role of a clinician in putting misleading ads in context for patients?

---

September 5th, 2012

Databases and Decisions

Harlan M. Krumholz, MD, SM

What’s an “excellent” mortality rate for elective ascending aorta/arch replacement, and how would we know?

---

August 24th, 2012

Is Bad News About Fibrates Getting Buried?

Harlan M. Krumholz, MD, SM

A meta-analysis about lipid-modifying therapies and risk for pancreatitis focuses on a benefit of statins but de-emphasizes potential harm from fibrates.

---

August 24th, 2012

Topol: The Clinical Trial World Is “Contrived”

Harlan M. Krumholz, MD, SM

Eric Topol says it’s time to “get rid of the randomized trial.” What do you say?

---